Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis
Fecal microbiota transplantation and probiotics have been tested/used as potential therapeutics against inflammatory bowel diseases (IBD). Here the authors use a bottom-up rational consortium design approach that combines well-characterized strains isolated from healthy human stool samples to produc...
Guardado en:
Autores principales: | Daniel van der Lelie, Akihiko Oka, Safiyh Taghavi, Junji Umeno, Ting-Jia Fan, Katherine E. Merrell, Sarah D. Watson, Lisa Ouellette, Bo Liu, Muyiwa Awoniyi, Yunjia Lai, Liang Chi, Kun Lu, Christopher S. Henry, R. Balfour Sartor |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5eb6b389fe5147e39c08cf643fd1bdcd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
COVID-19 and the Gut Microbiome: More than a Gut Feeling
por: Daniel van der Lelie, et al.
Publicado: (2020) -
Phytoplankton consortia as a blueprint for mutually beneficial eukaryote-bacteria ecosystems based on the biocoenosis of Botryococcus consortia
por: Olga Blifernez-Klassen, et al.
Publicado: (2021) -
Single strain control of microbial consortia
por: Alex J. H. Fedorec, et al.
Publicado: (2021) -
Majority sensing in synthetic microbial consortia
por: Razan N. Alnahhas, et al.
Publicado: (2020) -
Engineered microbial consortia: strategies and applications
por: Katherine E. Duncker, et al.
Publicado: (2021)